Spear Bio, Developer of the Next-generation Ultrasensitive Immunodiagnostics and Proteomics Platform, Completes Raise of Tens of Millions of US Dollars With Oversubscribed Seed Prime

WOBURN, Mass., Nov. 29, 2023 /PRNewswire/ — Spear Bio Inc., a Harvard University biotech spin-off developing scalable solutions for ultrasensitive detection of protein biomarkers announced the completion of a raise of tens of millions of US dollars with its Seed Prime.

Spear Bio Receives ISO 13485:2016 Certification

WOBURN, MA. Aug. 17, 2023– Ultrasensitive immunoassays developer Spear Bio has announced that it has received ISO certification for operating a “Quality Management System which complies with the requirements of ISO 13485: 2016.”

New Spear Bio Ultrasensitive Immunoassay Neutralizing Antibodies Test Kits for Covid Variants

Woburn, MA, July 10, 2023 – Ultrasensitive immunoassays developer Spear Bio is expanding its family of NAB-Sure SARS Cov-2 Neutralizing Antibodies test kits. Previously released kits included the original Wild Type strain and Omicron BA.4/5 variants. It has now added test kits for Omicron variants XBB.1.5 and BQ.1.1.

Spear Bio Co-Founder Feng Xuan to Present at Vaccines Summit this Month in Boston

WOBURN, Mass., May 15, 2023 /PRNewswire/ — Spear Bio co-founder, President & CTO, Feng Xuan, Ph.D. will be presenting at the upcoming Vaccines Summit (#VSBoston, May 22-24) at the Boston Marriott Newton Hotel. This summit brings together leading biotech and pharma industry experts, academics, and decision-makers for the latest vaccine R&D updates, global perspectives, collaboration, and networking.

Spear Bio expands NAB-Sure™ Assays to Support Study of SARS-CoV-2 Variants

NAB-Sure ™, the new cell-free SARS-CoV-2 neutralizing antibody assay will be featured at Vaccine Summit in Washington D.C. PRESS RELEASE Woburn, MA, October 11 2022 – Feng Xuan, Spear Bio’s Co-Founder and chief technology officer, will share insightful research and results featuring NAB-Sure™ – a new, ultrasensitive immunoassay – during the Vaccine Summit 2022.

Spear Bio Co-founder and CTO to present at Vaccine Summit

Spear Bio is expanding its NAB-Sure™ Neutralizing Antibody Test Kit product line with current SARS-CoV-2 variants. This addresses the need of researchers and vaccine developers faced with emerging SARS-CoV-2 variants as they continue to study immune responses to COVID-19 and protection durability of vaccines.

Immunoassay Technology Developer Spear Bio Presents Its NAB-Sure™ SARS-CoV2 Neutralizing Antibody Test Kit at the American Association of Clinical Chemistry’s Annual Event

Woburn, MA, August 31, 2022 – Developer of ultrasensitive protein detection platform, Spear Bio (www.spear.bio), presented its breakthrough immunoassay technology at the recent American Association of Clinical Chemistry’s scientific meeting and clinical lab expo, held in Chicago.

Wyss Institute at Harvard University launches SPEAR Bio

Wyss Institute at Harvard University launches SPEAR Bio to empower disease research, patient care, and drug development with its small-sample, ultrasensitive, protein-detection technology. Spear Bio is working towards commercializing its first assay, which accurately assesses levels of SARS-CoV-2-neutralizing antibodies in dried-blood spot samples. PRESS RELEASE By Benjamin Boettner (BOSTON)

Spear Bio’s NAB-Sure™ Test Kit Aids Analysis of COVID-19 Immune Response

New Neutralizing Antibody Test Kit Has High Sensitivity and Ability to Analyze Micro-Samples PRESS RELEASE Woburn, MA, August 22, 2022 – Pharmaceutical drug developers and healthcare researchers need innovative tools to understand COVID-19 immune response and validate vaccines and therapeutics critical to managing the pandemic.